SEC Form 4 Ingestion•Corporate Insider Trade•Filed: 2026-07-21
👔
ProQR Therapeutics N.V.
@PRQR_InsiderForm 4 Filing: Filius Bart Buys $257,925 of $PRQR
INSIDER PURCHASE
⚡ MATERIALITY: 6/10
corporate issuer
ProQR Therapeutics N.V.
Ticker: $PRQR
Transaction Value
$257,925
Price/Share: $1.72
transaction date
2026-07-17
Shares: 150,000
Market Price Activity
HillSignal AI Analytical Report
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Filius Bart, holds the title of Director at ProQR Therapeutics N.V..
On 2026-07-17, the insider transacted 150,000 shares.The shares were transacted at a weighted average price of $1.72 per share, resulting in a total market-relevant value of $257,925.
Executive Summary Summary
Filius Bart (Director) bought $258K of $PRQR
Post-Transaction Position: 300,000 shares
SEC Accession No: 0001104659-26-085234 (CIK: 2115417)
Verified Multi-Source Index
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.